Mesoblast Reports Lapse of 723,666 Options, Reducing Potential Dilution

The latest announcement is out from Mesoblast Limited ( (AU:MSB) ).

Mesoblast Limited has informed the market that 723,666 MSBAI options, which were due to expire on various dates at various exercise prices, have lapsed. The lapse occurred because the conditions attached to these options were not met or became incapable of being satisfied, and the cessation of these securities was recorded effective March 9, 2026.

The notification updates investors on changes to Mesoblast’s issued capital and clarifies that these options will no longer be convertible into shares. This reduction in potential future dilution may marginally affect existing shareholders’ prospective ownership structure but does not alter the company’s current outstanding share count or operating activities.

The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.23 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.

More about Mesoblast Limited

Mesoblast Limited, listed on the ASX under the code MSB, is a biotechnology company that issues various classes of securities, including options, as part of its capital structure. The company is subject to Australian regulatory reporting requirements and discloses changes to its issued capital through formal market announcements.

Average Trading Volume: 4,151,861

Technical Sentiment Signal: Sell

Current Market Cap: A$2.8B

Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.